NuCana (NCNA) Shares Outstanding (Weighted Average) (2016 - 2025)
NuCana's (NCNA) quarterly Shares Outstanding (Weighted Average) came in at $14.9 billion in Q4 2025, up 204791.13% year-on-year from N/an in Q4 2024, and up 204791.13% quarter-over-quarter from $7.3 million in Q4 2024.
NuCana (NCNA) Shares Outstanding (Weighted Average) (2016 - 2025) Analysis & Trends
NuCana has disclosed Shares Outstanding (Weighted Average) across 10 years of filings, most recently posting $14.9 billion for Q4 2025.
- Shares Outstanding (Weighted Average) for Q4 2025 came in at $14.9 billion, up 204791.13% year-over-year; the trailing twelve-month figure through Dec 2025 was $14.9 billion (up 204791.13% YoY), and the FY2025 annual result was $14.8 billion, up 203826.12% from the prior year.
- Shares Outstanding (Weighted Average) came in at $14.9 billion for Q4 2025 at NuCana, up from $7.3 million in the prior quarter.
- In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $14.9 billion in Q4 2025 to a low of $261994.9 in Q1 2021.
- The 5-year median for Shares Outstanding (Weighted Average) is $1.6 million (2021), against an average of $1.5 billion.
- Across the five-year window, Shares Outstanding (Weighted Average) plunged 39.94% in 2022 and surged 204791.13% in 2025, its largest moves.
- NuCana's Shares Outstanding (Weighted Average) stood at $2.8 million in 2021, then slipped by 12.65% to $2.5 million in 2022, then climbed by 6.78% to $2.6 million in 2023, then soared by 177.9% to $7.3 million in 2024, then soared by 204791.13% to $14.9 billion in 2025.
- The last three Shares Outstanding (Weighted Average) figures came in at $14.9 billion (Q4 2025), $7.3 million (Q4 2024), and $2.6 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 185,491.37 Bn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 400.00 Bn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 100.00 Bn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 118.76 Bn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | 417.01 Bn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 68.88 Bn |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 254.10 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 928.40 Mn |
| 10 | NuCana | 29.13 Bn | 29.13 Bn | - | 14.94 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 14.94 Bn |
| Dec 31, 2024 | 7.29 Mn |
| Dec 31, 2023 | 2.62 Mn |
| Jun 30, 2023 | 312,840.79 |
| Dec 31, 2022 | 2.46 Mn |
| Jun 30, 2022 | 302,235.41 |
| Dec 31, 2021 | 2.81 Mn |
| Sep 30, 2021 | 716,863.34 |
| Jun 30, 2021 | 503,182.17 |
| Mar 31, 2021 | 261,994.95 |
| Dec 31, 2020 | 2.70 Mn |
| Sep 30, 2020 | 709,776.52 |
| Jun 30, 2020 | 384,925.64 |
| Mar 31, 2020 | 153,823.80 |
| Dec 31, 2019 | 1.67 Mn |
| Sep 30, 2019 | 517,966.50 |
| Jun 30, 2019 | 385,893.79 |
| Mar 31, 2019 | 221,318.44 |
| Dec 31, 2018 | 1.66 Mn |
| Sep 30, 2018 | 417,104.94 |